Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Initiates Phase I Trial of Second-Gen TTR Amyloidosis Drug

Premium

Alnylam Pharmaceuticals this week said that it has begun dosing patients in a phase I study of its siRNA-based transthyretin-mediated amyloidosis treatment ALN-TTR02.

The trial is a randomized, single-blind, placebo-controlled, single-ascending dose study that will enroll about 32 healthy volunteers, the company said.

The primary endpoint is safety and tolerability of a single dose of ALN-TTR02, and study subjects will be enrolled in five sequential cohorts of increasing doses ranging from 0.01mg/kg to 0.50 mg/kg. Secondary objectives include serial measurement of circulating TTR serum levels through at least day 56 following a single dose.

ALN-TTR02 is a second-generation version of ALN-TTR01, which was found to safely trigger statistically significant reductions in serum levels of TTR protein, which characterizes TTR amyloidosis (GSN 12/1/2011).

The new drug uses a different delivery technology, the so-called MC3 lipid, which Alnylam has said is proprietary to the company. Tekmira Pharmaceuticals, which developed the lipid nanoparticles used in ALN-TTR01, has sued Alnylam over the rights to the MC3 technology.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.